Merck (MRK) Pushes Ahead With Oral HIV Regimens And 2027 FDA Review
Merck (MRK) Pushes Ahead With Oral HIV Regimens And 2027 FDA Review Yahoo Finance
Covered in this story
Analyst targets on Merck & Co.
- Freedom Broker: $149 → $140 by Nov 2027 via Investing.com Canada
- Guggenheim: $150 → $171 by Oct 2027 · Buy via Investing.com
- RBC Capital Markets: $145 → $145 by Oct 2027 · Sector Perform via MarketBeat
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $MRK yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Merck & Co. →Dalsna Finance is currently tracking 31 stories mentioning Merck & Co., the earliest published 12 Jun 2026.
Summary aggregated from Yahoo Finance's public RSS feed. The full reporting belongs to Yahoo Finance — please read it on their site.